Publications

Health Economics
- Evaluation of real-world health care resource utilization and associated costs in children with Juvenile Idiopathic Arthritis: A Canadian retrospective cohort study
  Grazziotin Lago L, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Johnson N, Luca NJ, Miettunen PM, Schmeling H, Marshall DA. Rheumatology and Therapy. May 2021 . (in press)
- Costs of hospital-associated care for patients with juvenile idiopathic arthritis in the Dutch healthcare system
  Kip MM, de Roock S, I van den Berg, Currie G, Marshall DA, Grazziotin Lago LR, Twilt M, Yeung RSM, Benseler SM, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Arthritis Care Res, May 2021 (doi: 10.1002/acr.24621). (in press)
- Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system
  Kip MA, de Roock S, Currie G, Marshall DA, Grazziotin Lago L, Twilt M. Expert Review of Pharmacoeconomics & Outcomes Research 2021;21(5):975-984.
- A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care
  Claire E. H. Barber^1,2, Marinka Twilt³, Tram Pham², Gillian R. Currie^2,3, Susanne Benseler³, Rae S. M. Yeung^4,5, Michelle Batthish⁶, Nicholas Blanchette^5,7, Jaime Guzman⁸, Bianca Lang⁹, Claire LeBlanc>10, Deborah M. Levy^4,5, Christine O’Brien⁵, Heinrike Schmeling³, Gordon Soon⁵, Lynn Spiegel⁵, Kristi Whitney⁵, and Deborah A. Marshall1^1,2*
- Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?
  Luiza Raquel Grazziotin^1,2, Gillian Currie^1,3, Michelle M. A. Kip⁴, Maarten J. IJzerman^4,8, Marinka Twilt⁵, Raymond Lee⁶, Deborah A. Marshall^1,2,7
- Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review
  Michelle M. A. Kip¹, Gillian Currie^2,3, Deborah A. Marshall², Luiza Grazziotin Lago², Marinka Twilt⁴,Sebastiaan J. Vastert⁵, Joost F. Swart⁵, Nico Wulffraat⁵, Rae S. M. Yeung⁶, Susanne M. Benseler⁴,Maarten J. IJzerman^1* and on behalf of the UCAN CAN-DU Health Economics Working Group